RecruitingRecruiting
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07909031 · Crescent Biopharma, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
About this study
The study will initially comprise 2 parts: dose escalation (Part 1) and backfill (Part 2). Population-defined dose optimization (Part 3) and expansion (Part 4) cohorts may be added based on emerging data.
Part 1: The study will follow a stepwise approach, beginning with a typical dose escalation in participants with selected indications of advanced solid tumors.
Part 2: Additional participants will enroll in the backfill part at select dose levels that have been previously cleared for safety by the safety review committee.
All participants will undergo a screening period, a treatment period, a safety follow-up period, and long-term follow-up. During the treatment period, participants will undergo clinical and safety assessments including disease assessment scans and blood laboratory safety, and pharmacokinetic assessments. After treatment ends, disease scans will continue until disease progression, and long-term follow-up visits will be conducted by telephone every 3 months.
Eligibility criteria
Inclusion Criteria:
* Life expectancy ≥ 3 months
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
* Adequate organ function and hematologic reserve based on laboratory parameters
* Have measurable disease defined by RECIST v1.1
* Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy
* Tumor indication specific inclusion criteria:
* Is progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types:
* Head and Neck Squamous Cell Carcinoma (HNSCC)
* Gastric/GEJ Cancer
* Biliary Tract Cancer (BTC)
* Esophageal Squamous Cell Carcinoma (ESCC)
* Ovarian Cancer
* Endometrial Carcinoma
* Cervical Cancer
* Non-Small Cell Lung Cancer (NSCLC)
Exclusion Criteria:
* Has malignancies other than disease under study within the past 3 years
* Has not adequately recovered from recent major surgery
* Has ongoing clinically significant toxicity related to prior therapy
* Has known sensitivity to any component of CR-002
* Has received prior treatment with an antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload.
* Has active central nervous system (CNS) metastases
* Has a medical or psychological condition that could interfere with study participation, increase risk, or affect interpretation of the study results
* NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.
Study design
Enrollment target: 219 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-10-21
Estimated completion: 2029-01
Last updated: 2026-11-02
Interventions
Drug: CR-002
Primary outcomes
- • Part 1: Dose Escalation - incidence and nature of dose-limiting toxicities (From the first dose of study drug up until approximately 1 month)
- • Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicable (From the first dose of study drug up until approximately 1 month)
- • All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (From the first dose of study drug until 90 days after the last dose of study drug)
Sponsor
Crescent Biopharma, Inc. · industry
Contacts & investigators
ContactCrescent Clinical Trials · contact · clinicaltrials@crescentbiopharma.com · 617-430-5595
All locations (3)
Clinical Study SiteRecruiting
Austin, Texas, United States
Clinical Study SiteRecruiting
Dallas, Texas, United States
Clinical Study SiteRecruiting
Fairfax, Virginia, United States